Entity
Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that develops and manufactures medications, primarily focused on diabetes and obesity treatments.
Why it’s in the news: It is in the news due to a series of drug trial failures, stock market volatility, and strategic licensing deals.
Latest on Novo Nordisk
- Novo Nordisk strikes second licensing deal since frosty capital-markets day
- Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
- STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
- STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
- STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
- Novo Nordisk Foundation to build $62M quantum chip plant in Copenhagen
- The Best Enterprise AI System Is One CFOs Are Allowed to Use
Connections
13 entities linked to Novo Nordisk across the news graph.
Under pressure from (1)